The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
AbstractBackground: There is conflicting data about the increased risk of pulmonary toxicity when granulocyte-stimulating factor (G-CSF) is given in combination with bleomycin. No clear consensus for management of patients with Hodgkin lymphoma (HL) who require G-CSF support exists. Our objective was to evaluate whether there is an increase in pulmonary toxicity in patients who receive bleomycin and G-CSF during treatment for HL. Materials and Methods: We conducted a single-center retrospective analysis of patients with Hodgkin Lymphoma from January 2003 until July 2015. All patients who received at least 1 dose of bleomycin and followed at our institution were included. Patients were evaluated for pulmonary toxicity starting from the day of first dose of bleomycin until 1 year after initiation of bleomycin. Data on pre-identified risk factors for pulmonary toxicity were also collected.Results: Fifty-four patients met inclusion criteria. Twenty-one patients received bleomycin alone, and 33 patients received bleomycin and G-CSF. There was no statistically significant (p = 0.50) difference in the development of pulmonary toxicity between the two groups. Crude hazard ratio for development of pulmonary toxicity in the bleomycin and G-CSF cohort was 1.58 (95% confidence interval, CI: 0.41-6.12). On multivariate analysis, the hazard ratio for development of pulmonary toxicity was 1.71 (95% CI: 0.43-6.81).Conclusion: This study does not find evidence that the combination of bleomycin and G-CSF increases the risk for bleomycin- induced pulmonary toxicity. We recommend G-CSF use in HL patients receiving bleomycin when needed to maintain dose intensity.
Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975; 36(1):252-9.
Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327(21):1478-84.
FDA Licensing Committee. Center for Drug Evaluation and Research Application Number: 103353/000; Filgrastim. 1991, Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/bla/pre96/103353Orig1s000.pdf
Azoulay E, Herigault S, Levame M, et al. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med. 2003; 31(5):1442-8.
Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005; 23(30):7614-20.
Ngeow J, Tan IB, Kanesvaran R, et al. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin’s lymphoma. Ann Hematol. 2011; 90(1):67-72.
Marri PR, Ristow K, Habermann TM, et al. Older patients and risk of developing and dying from bleomycin-induced lung toxicity. J Clin Oncol (Meeting Abstracts). 2014; 32(15_suppl):8584-8584.
Al-Jizani WA, Al-Mansour MM, Al-Fayea TM, et al. Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma. Future Oncol. 2015; 11(15):2149-57.
Younes A, Fayad L, Romaguera J, et al. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer. 2006; 42(17):2976-81.
Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348(24):2386-95.
Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011; 365(3):203-12.
NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. 2017. Version 1.2017 retrieved from:https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf.
NCCN Clinical Practice Guidelines in Oncology Myeloid Growth Factors. 2017. Version 1.2017. Retrieved from:https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf.
Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007; 18(2):376-80.
Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007; 137(6):545-52.
clinicaltrials.gov. Phase 3 Frontline Therapy Trial in Patients with Advanced Classical Hodgkin Lymphoma. https://clinicaltrials.gov/ct2/show/NCT01712490.
Van Barneveld PW, van der Mark TW, Sleijfer DT, et al. Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis. 1984; 130(6):1078-81.
O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003; 14(1):91-6.
Azambuja E, Fleck JF, Batista RG, et al. Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther. 2005; 18(5):363-6.
Jona A, Miltenyi Z, Poliska S, et al. Effect of Bleomycin Hydrolase Gene Polymorphism on Late Pulmonary Complications of Treatment for Hodgkin Lymphoma. PLoS One. 2016; 11(6):e0157651.
Johnson PW FM, Fossa A, et al. Response-adapted therapy based on interim FDA-PET scans in advanced Hodgkin lymphoma: First analysis of the safety of de-escalation and safety of escalation in the international RATHL study. Presented at the 13th International Conference on Malignant Lymphoma, Lugano, Switzerland. 2015.
NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer Related Infections Guidelines. 2017. Version 2.2017. Retrieved from: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.